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Heart failure (HF) is a chronic progressive disease that results in substantial morbidity, mortality, and expenditure of health care resources.[1](#anec12243-bib-0001){ref-type="ref"}, [2](#anec12243-bib-0002){ref-type="ref"} Approximately 1--2% of the adult population in developed countries suffer from HF, with the prevalence rising to ≥10% among persons 70 years of age or older.[3](#anec12243-bib-0003){ref-type="ref"} Clinical trials have established that cardiac resynchronization therapy (CRT) improves the clinical outcomes of patients with HF, reduced left ventricular ejection fraction (LVEF) and left ventricular conduction delays.[2](#anec12243-bib-0002){ref-type="ref"} The European Society of Cardiology (ESC) Guidelines for the diagnosis and treatment of acute and chronic HF 2012[4](#anec12243-bib-0004){ref-type="ref"} provide class I A recommendation for CRT treatment, with or without an implantable cardioverter defibrillator (ICD), in patients with symptomatic HF, sinus rhythm, QRS width ≥120 ms with left bundle branch block (LBBB) morphology and LVEF ≤35%. Although there has been a substantial increase in CRT implantation rates across Europe, marked differences among countries remain.[5](#anec12243-bib-0005){ref-type="ref"}, [6](#anec12243-bib-0006){ref-type="ref"} It is therefore likely that many patients who could potentially benefit from this therapy do not receive it. Since 2008, the European Heart Rhythm Association (EHRA) has published annual reports on CRT implantation rates in all represented countries.[7](#anec12243-bib-0007){ref-type="ref"} However, the penetration of CRT in comparison with the number of eligible patients has not been studied in detail. The aim of the present analysis was to examine the penetration of CRT (with or without ICD) on the basis of the prevalence and incidence of CRT indications in a number of ESC member countries covering Central, Southern and Eastern Europe and Israel.

METHODS {#anec12243-sec-0050}
=======

The following countries were considered in the analysis: Italy, Slovakia, Greece, Israel, Slovenia, Serbia, the Czech Republic, Poland, Romania, Hungary, Ukraine, and the Russian Federation. Each country was represented by a cardiologist, who actively contributed to the project.

CRT penetration was defined as the number of patients treated with CRT divided by the number of patients that, on the basis of ESC Guidelines class I A recommendation, should receive CRT; that is, the number of patients with a CRT implanted (CRT patients) in relation to the prevalence of CRT indications.

Assuming that the mean duration of recent CRT devices is 5 years,[8](#anec12243-bib-0008){ref-type="ref"} the number of CRT patients was conservatively estimated as the cumulative number of CRT implantations over 5 years (from 2007 to 2011), including replacements; this approximation minimizes the number of patients counted twice. Both CRT‐P (without ICD function) and CRT‐D (with ICD function) were considered. The sources of data used for the analysis were the annual EHRA White Book reports.[9](#anec12243-bib-0009){ref-type="ref"} All implantation rates were therefore cross‐validated by the country coordinator.

The prevalence of CRT indication was derived from the literature; for simplicity, this was assumed to be constant over a period of a few years. This hypothesis is plausible, in that: (1) in the short term (5 years), HF prevalence is fairly stable;[10](#anec12243-bib-0010){ref-type="ref"} (2) the ratio between the incidence and prevalence of CRT indication is roughly 1:10, which is similar to the ratio between the incidence and prevalence of HF, as reported below; (3) as the annual mortality rate in CRT‐indicated patients is about 10%,[11](#anec12243-bib-0011){ref-type="ref"} it approximately balances the incidence of new patients eligible for CRT. Figure [1](#anec12243-fig-0001){ref-type="fig"} shows the simplified hypothesis, in which the prevalence of CRT indication is constant.

![Simplified hypothesis in which prevalence of CRT indication is constant, since the mortality rate is compensated by the incidence of new eligible subjects.](ANEC-20-43-g001){#anec12243-fig-0001}

In order to estimate how many HF patients are indicated for CRT, three models were developed and compared: Model 1 (based on a report from the Italian Network on Congestive Heart Failure published by Baldasseroni et al.[12](#anec12243-bib-0012){ref-type="ref"}): patients with Sinus Rhythm, LBBB, and LVEF\<30% represent 10.8% of HF patients.Model 2 (based on a paper by Shenkman et al.[13](#anec12243-bib-0013){ref-type="ref"}): among patients with HF, those with QRS duration ≥120 ms and systolic dysfunction defined as LVEF \<45% account for about 14.1%.Model 3 (based on a report from the National Registry to Advance Heart Health (ADVANCENT) published by El‐Chami et al.[14](#anec12243-bib-0014){ref-type="ref"} and on data from the EuroHeart Survey[15](#anec12243-bib-0015){ref-type="ref"}): 28.9% of systolic (LVEF ≤40%) HF patients have sinus rhythm and QRS ≥120 ms,[14](#anec12243-bib-0014){ref-type="ref"} and, since systolic HF patients represent 36% of all HF patients,[15](#anec12243-bib-0015){ref-type="ref"} CRT indication---defined as LVEF ≤40%, sinus rhythm and QRS ≥120 ms---is present in about 10.4% of HF patients.

The consensus that emerges from the three models is that about 10% of patients with HF are indicated for CRT on the basis of current class I A guidelines.

Thus, considering that 1--2% of the general population is affected by HF,[3](#anec12243-bib-0003){ref-type="ref"} the prevalence of CRT indication in the general population is about 0.1--0.2%, which means 1000--2000 individuals per million population. This range can be defined as the full CRT penetration range.

Finally, calculations were made for the individual participating countries. The demographics of each country were taken from The EHRA White Book.[9](#anec12243-bib-0009){ref-type="ref"} The estimated number of CRT patients in each country was normalized per million inhabitants, that is, calculated as the sum of the last 5 years implantation rates, each normalized for the current country population. For each country, the number of CRT patients was compared with the full CRT penetration range, and CRT penetration was estimated.

In the field of implantable devices, once full penetration has been reached, that is, all indicated patients have received implants, the potential target for the therapy becomes equal to the annual incidence rate of indication. Thus, the incidence represents the real number of patients to treat every year.

The HF incidence values reported in the literature range from 0.13% to 1.44% in the general population.[3](#anec12243-bib-0003){ref-type="ref"}, [16](#anec12243-bib-0016){ref-type="ref"}, [17](#anec12243-bib-0017){ref-type="ref"}, [18](#anec12243-bib-0018){ref-type="ref"} For simplicity, we estimated HF incidence in a range of 0.1--0.2%, as reported above. Thus, the annual incidence of CRT indication was estimated in a range of 100--200 individuals per million. For each country, the number of patients who underwent implantation in the year 2011 (normalized for resident population) was compared with the range of incidence of CRT indication.

Provided the prevalence of eligible patients with HF is completely covered by CRT implants, the annual CRT implantation rate should fall into that range. This means that approximately all new patients indicated for CRT receive the therapy, which could be regarded as an ideal condition. When the penetration of CRT is partial, that range represents a minimum target. Achieving this target means that all newly eligible subjects, and possibly a portion of the remaining HF patients, will receive treatment.

RESULTS {#anec12243-sec-0060}
=======

Demographic and CRT implantation data in the various countries from 2007 to 2011 are shown in Table [1](#anec12243-tbl-0001){ref-type="table"}. Absolute and normalized EHRA White Book implantation data[9](#anec12243-bib-0009){ref-type="ref"} are reported. The last column displays normalized implantation data validated by the country\'s investigator, which were used to estimate CRT penetration. Figure [2](#anec12243-fig-0002){ref-type="fig"} shows the numbers of patients in whom CRT‐P and CRT‐D devices were implanted from 2007 to 2011 in each country. The range of CRT indication prevalence represents the estimated range of subjects that should be treated, according to the guidelines. For comparison between countries, both data are normalized per million inhabitants. The estimated CRT penetration in each country is shown in Figure [3](#anec12243-fig-0003){ref-type="fig"}. The range is calculated on the basis of HF prevalence, which is between 1% and 2% of the general population.

###### 

Population and Annual CRT Implant Rates Normalized per Million Inhabitants of Each Country

                              EHRA White     Normalized EHRA   Normalized Validated                                       
  -------------------- ------ ------------- ----------------- ---------------------- -------- ---- ----- ----- ---- ----- -----
  Italy                 2007  58,147,733          1537                 8200            9737    26   141   167   26   141   167
                        2008  58,145,321          1500                 9500           11,000   26   163   189   26   163   189
                        2009  58,145,321          1550                 8800           10,350   27   151   178   27   151   178
                        2010  60,748,965          1800                10,000          11,800   30   165   194   30   165   194
                        2011  61,016,804          2000                10,380          12,380   33   170   203   33   170   203
  Slovakia              2007  5,402,273            30                   81             111     6    15    21    6    15    21
                        2008  5,455,407            41                  164             205     8    30    38    8    30    38
                        2009  5,460,862            72                  221             293     13   40    54    13   40    54
                        2010  5,470,306            89                  317             406     16   58    74    16   58    74
                        2011  5,477,038            78                  251             329     14   46    60    14   46    60
  Greece                2007  10,964,020           85                  238             323     8    22    29    7    16    23
                        2008  10,722,816           90                  272             362     8    25    34    7    22    29
                        2009  10,733,539           386                 429             815     36   40    76    7    29    36
                        2010  10,749,943           48                  323             371     4    30    35    5    34    39
                        2011  10,760,136           32                  364             396     3    34    37    5    32    37
  Israel                2007  7,112,359            79                  489             568     11   69    80    11   69    80
                        2008  7,112,359            123                 699             822     17   98    116   17   98    116
                        2009  7,233,269            154                 838             992     21   116   137   21   116   137
                        2010  7,353,985            105                 720             825     14   98    112   25   142   167
                        2011  7,473,052            100                 527             627     13   71    84    27   154   181
  Slovenia              2007  2,009,245            39                   2               41     19    1    20    19    1    20
                        2008  2,007,711            37                   19              56     18    9    28    18    9    28
                        2009  2,005,703            36                   31              67     18   15    33    18   15    33
                        2010  2,003,136            36                   57              93     18   28    46    18   28    46
                        2011  2,000,092            35                   55              90     17   27    45    17   27    45
  Serbia                2007  7,600,000            110                  95             205     14   13    27    14   13    27
                        2008  7,413,882            158                  69             227     21    9    31    21    9    31
                        2009  7,376,813            173                  86             259     23   12    35    23   12    35
                        2010  7,344,847            73                   64             137     10    9    19    10    9    19
                        2011  7,310,555            226                  67             293     31    9    40    31    9    40
  Czech Republic        2007  10,391,130           313                 608             921     30   59    89    30   59    89
                        2008  10,220,911           492                 669            1.161    48   65    114   48   65    114
                        2009  10,210,690           551                1.033           1.584    54   101   155   54   101   155
                        2010  10,201,707           301                 947            1.248    30   93    122   30   93    122
                        2011  10,190,213           289                1.171           1.460    28   115   143   28   115   143
  Poland                2007  38,518,241           440                 140             580     11    4    15    11    4    15
                        2008  38,500,696           517                 821            1.338    13   21    35    13   21    35
                        2009  38,500,696           606                1.741           2.347    16   45    61    16   45    61
                        2010  38,463,689           431                1.913           2.344    11   50    61    11   50    61
                        2011  38,441,588           387                2.152           2.539    10   56    66    10   56    66
  Romania               2007  22,246,862           89                   34             123     4     2     6    4     2     6
                        2008  22,246,862           75                   24              99     3     1     4    3     1     4
                        2009  22,224,615           100                  40             140     4     2     6    4     2     6
                        2010  21,959,278           171                  42             213     8     2    10    8     2    10
                        2011  21,904,551           159                  61             220     7     3    10    7     3    10
  Hungary               2007  9,956,108            275                 218             493     28   22    50    28   22    50
                        2008  9,930,915            304                 217             521     31   22    52    31   22    52
                        2009  9,901,122            389                 281             670     39   28    68    39   28    68
                        2010  9,992,339            396                 436             832     40   44    83    40   44    83
                        2011  9,976,062            454                 352             806     46   35    81    46   35    81
  Ukraine               2007  NA                   NA                   NA              NA     NA   NA    NA    0     0     0
                        2008  NA                   NA                   NA              NA     NA   NA    NA    1     0     1
                        2009  NA                   NA                   NA              NA     NA   NA    NA    1     0     1
                        2010  45,415,596           45                   1               46     1     0     1    1     0     1
                        2011  45,134,707           49                   6               55     1     0     1    1     0     1
  Russian Federation    2007  140,702,094          166                  60             226     1     0     2    1     0     2
                        2008  140,702,094          322                 123             445     2     1     3    2     1     3
                        2009  139,998,584          346                 116             462     2     1     3    2     1     3
                        2010  139,390,205          317                 149             466     2     1     3    2     1     3
                        2011  138,739,892          365                 428             793     3     3     6    3     3     6
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![Estimate of patients already treated with CRT in each country compared with the possible range of patients indicated for therapy, both normalized per million population (range depending on the HF prevalence range).](ANEC-20-43-g002){#anec12243-fig-0002}

![Estimated CRT penetration range in each country, represented as a range depending on the HF prevalence range.](ANEC-20-43-g003){#anec12243-fig-0003}

Figure [4](#anec12243-fig-0004){ref-type="fig"} shows the number of patients treated with CRT in each country from 2007 to 2011, normalized per million population, compared with the range of CRT indication incidence; the latter represents the number of new patients annually eligible for CRT and is also normalized per million inhabitants (range depending on the HF incidence range, estimated at 0.1--0.2% of the general population).

![Number of patients treated with CRT in each country from 2007 to 2011, compared with the range of CRT indication incidence, which represents the number of new patients annually eligible for CRT; both are normalized per million inhabitants (range depending on the HF incidence range).](ANEC-20-43-g004){#anec12243-fig-0004}

Italy is the country where CRT has the highest penetration: from 47% to 93% of patients indicated already have a device implanted. On the basis of the simplified model adopted, this means that, in the coming years, the number of CRT implantations should reach a value equal to the CRT indication incidence, which is estimated to be in the range of 100--200 implantations per million population.

Israel and the Czech Republic also display a good degree of therapy penetration, ranging from 34% to 68% and from 31% to 62%, respectively. If maintained, the trend in CRT implantations seen in both countries in recent years will probably lead to greater penetration of the therapy in the near future.

CRT penetration is still only partial in Hungary, where less than one of three indicated patients is treated. The figures are even lower in Slovakia and Poland, where only one of four receives the therapy. As the implantation rate in these countries is still low, CRT penetration will probably slowly improve in the near future.

In Slovenia, Greece, and Serbia, more than 80% of indicated patients are still not treated, and CRT adoption in recent years has also been very low.

In Romania, the Russian Federation and Ukraine, CRT penetration is very poor, since less that 5% of patients that could benefit from the therapy are currently treated, and implantation rates are negligible.

The number of CRT‐D devices as a percentage of total CRT implants is seen to have varied year by year in the different countries, as shown in Figure [5](#anec12243-fig-0005){ref-type="fig"}. In Italy and Israel, the proportion of CRT‐D devices exceeds 80%, and has remained stable over the last 5 years. Slovakia, Greece, the Czech Republic, and Poland currently adopt CRT‐D in more than 75% of cases, with the last two countries showing an increasing trend year by year. In Slovenia, CRT‐D devices are increasing and currently account for about 60% of all CRT implants. In the Russian Federation, Hungary, Romania, Serbia, and Ukraine, CRT‐P devices are mainly used.

![CRT‐D devices as a percentage of total CRT implants in each country from 2007 to 2011.](ANEC-20-43-g005){#anec12243-fig-0005}

The main barriers to CRT penetration---as identified by the physicians representing each country---are summarized in Table [2](#anec12243-tbl-0002){ref-type="table"}.

###### 

Considerations and Main Barriers to Therapy Adoption in Each Countries

  Country              Considerations on CRT Adoption and Main Barriers to Therapy Penetration
  -------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Italy                Early adoption of CRT, currently well penetrated, thanks to: reimbursement covered by the national health care system, very high number of implanting centers (approximately 350), training activities, good cooperation with referral physicians, and early adoption of "gray zone" indications, such as atrial fibrillation.
  Israel               Good penetration of CRT and strict adherence to implantation guidelines, assisted by recording of patients' data in the Israeli ICD Registry, which is highly encouraged and covers almost 100% of high‐power device implantations. Lack of specific reimbursement for high‐power device implantation procedures to public hospitals is a disincentive to investment in personnel, equipment, and more electrophysiology laboratories.
  Czech Republic       Despite limited financial resources, CRT has good penetration. Insurance companies control center accreditation for CRT (currently 19, two of which for CRT‐P only) and verify, through specific registries, that every implantation complies with guidelines. Important role of education and training activities for implanters and clinical cardiologists and "Hub and spoke" model facilitate good referral of patients.
  Hungary              The main obstacle to CRT penetration is that reimbursement is limited. To increase CRT penetration, the country is intentionally favoring the implantation CRT‐P over CRT‐D devices.
  Slovakia             The main barriers to a wider adoption of CRT are limited financial resources and reimbursement policies. Another obstacle is the low awareness of guidelines among physicians working in medical departments in general hospitals, and the resulting insufficient referral to the four centers implanting CRT.
  Poland               CRT penetration is severely limited by the budget allocated by the government to the implanting centers.
  Slovenia             One of the main barriers is the lack of operators, since before 2005 device implantation was done by surgeons. Other obstacles are limited financial resources and low awareness of guidelines.
  Greece               The main barriers to the penetration of CRT are lack of operators and trained personnel, low awareness of guidelines and, recently, considerable reduction of hospital budgets and, consequently, the limitation of implantations.
  Serbia               The economic situation and consequent limited financial resources are the main reasons for the predominance of CRT‐P. The strategy of the national working group for pacemaker therapy is to increase CRT‐P therapy over CRT‐D for better penetration. Awareness of guidelines is good owing to informational and educational campaigns.
  Romania              The small number of devices provided by the national health care system means that CRT penetration is negligible. The overwhelming majority of CRT‐D devices are paid for by patients, which also explains the predominance of CRT‐P.
  Russian Federation   CRT penetration is very poor. The main barriers are the lack of reimbursement: devices allocated by the national health care system are few; as patients often pay for the procedure personally, they prefer CRT‐P for economic reasons.
  Ukraine              CRT penetration and current implantation rates are negligible. Financial resources allocated to supplying devices are scant and implanting physicians lack specific competence.
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DISCUSSION {#anec12243-sec-0070}
==========

In the present study, we estimated the potential population eligible for CRT on the basis of HF epidemiology and, for the first time, we evaluated the penetration of CRT in terms of prevalence and incidence in different countries.

According to current ESC guidelines, CRT is fully recognized as having a class I indication, level of evidence A, for patients with symptomatic HF, LVEF ≤35%, sinus rhythm, and cardiac dyssynchrony, which is currently defined as QRS duration ≥120 ms. The potential CRT target has been estimated by Linde at al.,[19](#anec12243-bib-0019){ref-type="ref"} who concluded that approximately 0.1% of the adult population should receive a CRT device. This percentage is consistent with our estimate of CRT indication prevalence. However, our study is the first to estimate CRT penetration, defined as the number of patients with a device already implanted as a proportion of the eligible population. Furthermore, considering that, once CRT has fully penetrated, the potential target for the therapy is equal to the annual incidence of CRT indication, we also estimated the incidence of CRT indication, defined as the annual number of new patients eligible for CRT, and compared this with annual implantation rates. This number is extremely important since it approximately represents the annual number of patients that we will be called to treat in the years to come. Finally, this analysis showed that, while CRT is universally accepted as a therapy for HF, there are significant differences in terms of penetration among the various countries considered.

FACTORS AFFECTING DIFFERENCES IN CRT PENETRATION AND OPPORTUNITIES TO PROMOTE CRT ADOPTION {#anec12243-sec-0080}
==========================================================================================

There are many reasons for the disparities in CRT penetration observed in different countries. Reimbursement by the national health care system for CRT device implantation seems to be an essential requirement for adequate adoption of the therapy; in countries where the cost of the procedure is not reimbursed or is only partially reimbursed, CRT penetration is very low and the use of CRT‐P devices is predominant. The issue of the cost‐effectiveness of CRT has been addressed in several papers.[20](#anec12243-bib-0020){ref-type="ref"}, [21](#anec12243-bib-0021){ref-type="ref"} CRT‐P appears to be a highly cost‐effective addition to medical therapy in eligible patients, while CRT‐D is cost‐effective when life expectancy at the time of implantation is reasonable. Indeed, CRT has been shown to be cost‐effective even in the ninth decade.[21](#anec12243-bib-0021){ref-type="ref"} However, the problem is that cost‐effectiveness analysis is difficult to transfer from one country to another, especially when the costs of labor, drugs, and medical devices vary significantly. Therefore, it is important to obtain country‐specific data, since such data could convince governments to allocate health resources differently and/or prompt local health care insurers to reimburse CRT.

Another important factor in the adequate adoption of CRT is the availability of qualified personnel and the equipment required for successful implantation (C arm with the possibility of cine‐loop acquisition, etc.). In some countries, the training of specialists remains a substantial issue. Training fellowships granted by the EHRA and/or organized directly by industry may help in this direction.

The adoption of CRT also depends on the awareness of physicians and patients. It is therefore of the utmost importance to "educate" referring physicians and to establish referral pathways. Campaigns to raise public awareness of CRT are another important component of this process.

STUDY LIMITATIONS {#anec12243-sec-0090}
=================

The main limitation of the present study is that estimates of CRT penetration and of the prevalence and incidence of CRT indication are expressed as a wide range. This is due to the fact that both the prevalence and the incidence of HF are reported as wide ranges in epidemiologic studies. Since the prevalence of HF ranges from 1% to 2%, the estimated penetration of the therapy ranges from one percentage value to another which is twice as high; although this does not affect comparisons among countries, the accuracy of the estimated CRT penetration in any single country is low. Once further epidemiologic studies have better determined the value of HF prevalence, the present analysis will be able to provide a more accurate estimate of CRT penetration.

Another limitation of the present analysis is that we used rough HF prevalence and incidence values, which were not adjusted for age. Thus, comparisons among countries considered the same range of prevalence and incidence of CRT indication in all cases. Since HF is highly correlated with age,[3](#anec12243-bib-0003){ref-type="ref"} the age distribution of the population will presumably influence the estimated range CRT indication in terms of prevalence and incidence, and consequently the estimate of CRT penetration. For example, 26% of the Italian population is older than 60 years, while in the Russian Federation the figure is 18%.^22^ A further analysis should consider the epidemiology of HF adjusted for age, in order to refine estimates of CRT penetration and better compare different geographic areas.

CONCLUSIONS {#anec12243-sec-0100}
===========

CRT penetration differs markedly among the countries analyzed. The main obstacles to patient recruitment are cultural and economic; cultural barriers are related to the awareness, dissemination, and implementation of guidelines, while economic barriers are mainly related to the lack of reimbursement for the procedure in several countries.
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